Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Immunotherapy May Hold the Key to Attacking HPV-Associated Cancers

August 14th 2015

An improved understanding of the natural history of HPV, its interaction with the host immune system, and the distinct molecular alterations underlying HPV-positive cancers, are fueling development of new drugs, particularly immunotherapies geared toward generating an HPV-specific immune response.

Efficacy Maintained, QoL Improved With Radiation Dose Reductions in Oropharyngeal Cancer

July 24th 2015

Barbara Ann Burtness, MD, discusses the impact of two studies examining reductions in radiation and chemotherapy dose in low-risk HPV-associated oropharyngeal cancer.

Pembrolizumab Benefit in SCCHN Confirmed in Expansion Study

July 24th 2015

Tanguy Y. Seiwert, MD, discusses the significance of the expansion results of KEYNOTE-012 for advanced squamous cell carcinoma of the head and neck.

Study Adds Pembrolizumab to Paradigm for Certain Head and Neck Cancers

July 24th 2015

A group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.

Olanzapine Shown to Control CINV in Patients With Esophageal, Head and Neck Cancer

June 15th 2015

Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.

Dr. Seiwert on Pembrolizumab in Head and Neck Cancer

May 29th 2015

Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Dr. Loren Scott Michel on HPV-Associated Oropharyngeal Cancer

April 1st 2015

Loren Scott Michel, MD, Assistant Professor Medicine, Washington University, medical oncologist Siteman Cancer Center, discusses the link between human papillomavirus (HPV) and oropharyngeal cancers.

Investigational Therapies for Thyroid Cancer

March 27th 2015

Frontline Treatment Selection in RAI-Refractory DTC

March 27th 2015

Optimizing Treatment With Lenvatinib in Thyroid Cancer

March 27th 2015

Lenvatinib in RAI-Refractory Thyroid Cancer

March 27th 2015

DECISION Trial Supports Sorafenib in Thyroid Cancer

March 27th 2015

Treatment of Recurrent Thyroid Cancer

March 27th 2015

Multidisciplinary Thyroid Cancer Care

March 27th 2015

Radioactive Iodine Treatment for Thyroid Cancer

March 27th 2015

Thyroid Cancer Risk Assessment and Diagnosis

March 27th 2015

Medullary Thyroid Cancer: What is Available?

March 4th 2015

More Personalized Therapy Needed to Improve Survival

March 4th 2015

Current and Future Targets in Thyroid Cancer

March 4th 2015

Key Findings From DECISION and SELECT Trials

March 4th 2015